Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04456153 · ClinicalTrials.gov registry record · Phase 2
Atovaquone for Treatment of COVID-19
A Phase 2 study, sponsored by University of Texas Southwestern Medical Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 60
- Enrollment target
NCT04456153 is a Phase 2 study that has completed, run by University of Texas Southwestern Medical Center. The registered enrollment target is 60 participants.
The verdict
NCT04456153, a Phase 2 study, has completed, sponsored by University of Texas Southwestern Medical Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 60 participants
- Enrollment target
Study Summary
The purpose of the current study is to accelerate the use of a clinically available therapeutic already FDA-approved for other indications in the setting of pandemic COVID-19 addressing a serious and emergent unmet medical need. This is a randomized, double-blind study of atovaquone therapy in adult participants hospitalized with COVID-19. Approximately 60 participants who meet all eligibility criteria may be randomized in a 2:1 atovaquone/placebo ratio into one of the following treatment groups: Treatment Group 1: continued standard of care therapy together with an oral dose of 1500 mg atovaquone twice daily (administered with a meal or snack) for up to 10 days Treatment Group 2: continued standard of care therapy together with matching placebo
Interventions
- DRUG Experimental Group
- DRUG Placebo Group
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2020-07-22 |
| Est. Completion | 2021-01-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04456153
The ClinicalTrials.gov registry entry for NCT04456153 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Texas Southwestern Medical Center, which has 837 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Experimental Group is the first listed.
NCT04456153 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04456153 about?
NCT04456153 is a clinical study titled "Atovaquone for Treatment of COVID-19". The purpose of the current study is to accelerate the use of a clinically available therapeutic already FDA-approved for other indications in the setting of pandemic COVID-19 addressing a serious and emergent unmet medical need. This is a randomized, double-blind study of atovaquone therapy in adul...
What is the current status of trial NCT04456153?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 60 participants. The study started on 2020-07-22. Estimated completion is 2021-01-31.
What interventions are being tested in trial NCT04456153?
The interventions under investigation include: Experimental Group (DRUG), Placebo Group (DRUG).
Who is sponsoring clinical trial NCT04456153?
This trial is sponsored by University of Texas Southwestern Medical Center, which has 837 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.